NRx Pharmaceuticals has received FDA confirmation of a path forward for its ketamine-based treatment NRX-100, following an in-person Type C guidance meeting at FDA headquarters. The company plans to submit a New Drug Application by June 2026 for treating depression, including patients with suicidality.
At the meeting, attended by leaders of the FDA Division of Psychiatry Products, the FDA Office of Neuroscience, and the FDA Center for Drug Evaluation and Research, the agency confirmed it will review existing Adequate and Well Controlled Clinical Trial data as Substantial Evidence of Efficacy together with Real World Evidence from Osmind, Inc. as confirmatory evidence. No additional clinical trials were requested.
In clinical trials, ketamine demonstrated dramatic superiority to placebo and active placebo, with non-inferiority versus electroshock therapy. The drug showed statistically significant reduction in suicidal ideation. Notably, electroshock therapy—the only currently approved treatment for suicidal ideation—demonstrated a 30% incidence of memory loss, whereas ketamine did not. Preliminary analysis of Real World Evidence confirms the effectiveness of intravenous ketamine in reducing both depression and suicidal ideation.
Based on the FDA meeting, NRx will pursue a primary indication to treat depression in patients with severe depression who may have suicidal ideation, expanding from its original plan targeting only those with suicidal ideation. According to the CDC, more than 16 million Americans experience depression each year and 3.6 million Americans contemplate suicide. The FDA also confirmed that no additional nonclinical data would be required and that no bridging studies would be needed to support the preservative-free formulation, for which the company anticipates at least three years of room temperature shelf stability. In addition to the pending NDA for NRX-100, NRx has a pending Abbreviated New Drug Application for preservative-free ketamine under its current label for use in anesthesia, with an FDA Summer 2026 decision date.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://menafn.com/1110866066/Nrx-Pharmaceuticals-NasdaqNRXP-Confirms-Path-To-New-Drug-Application-With-Real-World-Data-And-Broader-Proposed-Indication-For-NRX-100-Ketamine-Following-Type-C-FDA-Meeting